Seeking men and women with advanced relapsed, refractory, or resistant hematological (blood) cancer with an IDH mutation that has not responded or stopped responding to prior treatment for participation in a study of an investigational drug.
Participants in this study will receive the investigational drug as a tablet taken by mouth. Frequent study visits taking up to 3 hours are required while the best dose is being assessed. After the second 28-day cycle the study visits are only on the 1st day of the cycle.
What we're hoping for
We are studying what is the maximum safe dose of an investigational drug and whether it is safe and effective for advanced relapsed, refractory, or resistant hematological cancer with an IDH mutation.
ClinicalTrials.gov Identifier: NCT04764474